A Case of SGLT2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis.

MedStar author(s):
Citation: Cureus. 14(10):e30106, 2022 Oct.PMID: 36381906Institution: MedStar Union Memorial HospitalDepartment: Internal Medicine | Internal Medicine ResidencyForm of publication: Journal ArticleMedline article type(s): Case ReportsSubject headings: IN PROCESS -- NOT YET INDEXEDYear: 2022ISSN:
  • 2168-8184
Name of journal: CureusAbstract: While rare, serious adverse effects including euglycemic diabetic ketoacidosis (EDKA) have been associated with sodium-glucose cotransporter-2 inhibitor (SGLT2i) use. We present an interesting case of SGLT2i-induced EDKA occurring two years after initiation of therapy. Most patients with EDKA recover with prompt recognition and treatment. Patient education about identifying early signs remains a cornerstone of early identification and response to SGLT2i-induced EDKA. Copyright © 2022, Rao et al.All authors: Kumar K, Rao SJ, Saleh NFiscal year: FY2023Digital Object Identifier: Date added to catalog: 2022-12-13
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 36381906 Available 36381906

While rare, serious adverse effects including euglycemic diabetic ketoacidosis (EDKA) have been associated with sodium-glucose cotransporter-2 inhibitor (SGLT2i) use. We present an interesting case of SGLT2i-induced EDKA occurring two years after initiation of therapy. Most patients with EDKA recover with prompt recognition and treatment. Patient education about identifying early signs remains a cornerstone of early identification and response to SGLT2i-induced EDKA. Copyright © 2022, Rao et al.

English

Powered by Koha